I think the goal has always been (from my conversation with Tim Whitten) for Insmed to be a viable, stand-alone biotech company. Lewis will release the final phase 3 data sometime between now and December in a biotech conference according to Zacks. Zacks also reported that Insmed will be negotiating CF approval with the FDA. That was new! Also, some new information was unveiled at the NCAF and it was promising to say the least! It also appears to have panicked the bashers, heh, heh, heh....
For a God fearing man as you claim to be you are spreading false statements. I call them lies. For example, you claim that INSM is going to negotiate an FDA APPROVAL for CF. I just want to know when FDA approval for drugs was up for negotiation.
In reality, the FDA makes its decision and you then go through the protocols if you get a big fat CRL OR DENIAL. Then you can appeal.
Jesse, I'll be patient.ALL Bios say they want to be a stand alone.....until someone (especially a hedge fund manager is offered a good premium.) Insmed is not a buyout candidate because of unknowns, approvals NTM data etc. The Zacks article was old and the data presented was the hype that become a nuthin last week (except for a heads up tweet). Insmed has told you they do not plan to trial or to file in the U.S. You are either a complete fool or a liar., and lastly "bashers" or "shorts" are bad guys to you but since Insmed is down 80% since you got here, you may want to listen... Have a nice day